Education
About Us
Working with TipRanks
Follow Us
OncoArendi Therapeutics SA (DE:1B1)
:1B1
1B1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.22 - €3.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€35.95M
Enterprise Value€193.10M
Total Cash (Recent Filing)€40.66M
Total Debt (Recent Filing)€6.69M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Sep 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding20,603,155
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
1B1 FAQ
What was OncoArendi Therapeutics SA’s price range in the past 12 months?
OncoArendi Therapeutics SA lowest stock price was €1.22 and its highest was €3.15 in the past 12 months.
What is OncoArendi Therapeutics SA’s market cap?
OncoArendi Therapeutics SA’s market cap is €35.95M.
When is OncoArendi Therapeutics SA’s upcoming earnings report date?
OncoArendi Therapeutics SA’s upcoming earnings report date is Sep 30, 2025 which is today.
How were OncoArendi Therapeutics SA’s earnings last quarter?
Currently, no data Available
Is OncoArendi Therapeutics SA overvalued?
According to Wall Street analysts OncoArendi Therapeutics SA’s price is currently Overvalued.
Does OncoArendi Therapeutics SA pay dividends?
OncoArendi Therapeutics SA does not currently pay dividends.
What is OncoArendi Therapeutics SA’s EPS estimate?
OncoArendi Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoArendi Therapeutics SA have?
OncoArendi Therapeutics SA has 20,603,155 shares outstanding.
What happened to OncoArendi Therapeutics SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OncoArendi Therapeutics SA?
Currently, no hedge funds are holding shares in DE:1B1
Company Description
OncoArendi Therapeutics SA
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Technical Analysis
Biomaxima SA
―
Genomtec SA
―
Ryvu Therapeutics SA
―
Captor Therapeutics SA
―
Mabion SA
―